CCMs consist of clusters of enlarged endothelial channels ('caverns') that are arranged back to back to form densely packed sinusoids with little or no intervening brain parenchyma 1,2 . These lesions lack pericytes and elastic tissue, such that the vessel walls are thin, leaky and lack subendothelial support and an intact basal lamina. As compared to normal vessels, ultrastructural analysis of CCM lesions has revealed a decreased number of perictyes, endothelial detachment from the basal lamina and ruptures in the luminal endothelium, probably because of reduced and/or damaged intercellular junctions 3 . CCMs are found almost exclusively in the neurovasculature of the central nervous system (CNS, i.e., brain and retina) 4,5 , and they result in an increased risk for stroke, seizures and focal neurological deficits 1,2 . Currently, the only treatment for CCM is surgical resection.
1 0 3 4 VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 nature medicine the same pathway as CCM3 in cardiovascular development 22, 23 . We recently found that CCM3 and STK24 negatively regulate exocytosis 24 , a process wherein a cell directs the contents of secretory vesicles toward the extracellular space. These membrane-bound vesicles contain soluble proteins to be secreted into the extracellular environment and membrane proteins and lipids to be incorporated into the cell membrane. The size and contents of exocytic vesicles (also called granules) vary, and these characteristics are highly cell-type dependent. Exocytosis is accomplished by the fusion of secretory vesicles with the plasma membrane through the assembly of the soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) complex. Before membrane fusion, additional proteins mediate and regulate the initial interaction between vesicles and the acceptor membrane. These proteins include the plasma membrane proteins syntaxins; synaptosomal-associated proteins (SNAPs); vesicle-associated membrane proteins (VAMPs); the Rab family of small GTPases; the exocyst; and numerous other regulatory proteins. Among these regulatory proteins is the UNC13 family, which consists of UNC13A-D (ref. 25 ). UNC13B and UNC13D contain two separate Ca 2+ -binding C2 domains (C2A and C2B), and both UNC13B and UNC13D are involved in the tethering of granules to plasma membranes through the binding of their C2B domains to membrane lipids during granule docking and priming, before vesicle fusion with the plasma membrane. Our previous mechanistic studies suggested that CCM3 and STK24, by inhibiting UNC13 family proteins, regulate exocytosis and neutrophil degranulation 24 . The exocytic machinery that drives vesicle trafficking and membrane fusion in endothelial cells is similar to that found in neurons and neutrophils 26 . Endothelial cells contain the Weibel-Palade body (WPB), a type of secretory vesicle that releases von Willebrand factor (vWF) and P-selectin during inflammation. Moreover, ANGPT2 is released from WPBs in endothelial cells 27, 28 . ANGPTs (ANGPT1 and ANGPT2) are endothelial growth factors that bind to the tyrosine kinase receptor TIE2 (encoded by Tek), cooperatively regulating endothelial cell adherens junction-dependent vascular stability and blood-vessel formation during angiogenesis 29 .
In the present study, our observation that ANGPT2 levels are increased in both mouse and human CCM lesions prompted us to explore the role of the CCM3-UNC13 network in the regulation of the release of ANGPT2 and the implications of this regulation for CCM lesion development.
RESULTS

Mice with endothelial-cell-inducible Pdcd10 deletion develop CCM lesions
To obtain mice with tamoxifen-inducible, endothelial-specific deficiency of CCM3, we used Cdh5-CreERT2;Pdcd10 fl/fl mice (hereafter termed Pdcd10 ECKO mice). We first documented that the Cdh5-CreERT2 allele drove tamoxifen-inducible, endothelial-specific expression by mating Cdh5-CreERT2 mice with mT/mG-reporter mice. Feeding tamoxifen to Cdh5-CreERT2;mT/mG pups from postnatal (P)1 to P3 resulted in the induction of mG (EGFP) expression specifically in the vasculature of multiple tissues, including brain ( Supplementary Fig. 1a ). Next, we induced endothelial-cell-specific deletion of Pdcd10 in Pdcd10 ECKO pups immediately after birth (Supplementary Fig. 1b,c) . Pdcd10 ECKO , but not wild-type (WT) (Pdcd10 fl/fl ) pups, rapidly developed CCM lesions with dilated capillaries in the cerebellum, with onset at P5 and large lesions evident at P10 (Fig. 1a) . No Pdcd10 ECKO pups survived beyond P15 (n > 50). CCM lesions (>10,000 µm 2 ) were detected primarily inside the granule cell layers of the cerebellum of Pdcd10 ECKO mice, and lesion size was greatly enlarged at P10, as compared to P5 ( Fig. 1a-c) . CCM lesions in humans are formed by enlarged and irregular blood vessels that often result in cerebral hemorrhage. FITC-dextran perfusion at P10 showed that FITC-dextran was constrained inside the capillary beds of the brains and retina in WT mice, but was diffused to surrounding tissues in the cerebellum of Pdcd10 ECKO mice ( Fig. 1d-f ). Evans blue-dye permeability assay also showed increased vascular leakage in the cerebellum of Pdcd10 ECKO mice, as compared to WT mice ( Fig. 1g) . Venous malformations were also detected at the periphery of the retinal vascular plexus ( Fig. 1h-j) , but not in skin or liver, as visualized by isolectin and CD31 staining. The retina in Pdcd10 ECKO mice was leaky, as indicated by hemorrhage in freshly isolated retinas and by visualization using a FITC-dextran perfusion assay ( Supplementary Fig. 2a,b ).
CCM lesions exhibit disrupted endothelial cell junctions with increased ANGPT2 expression
To study the mechanisms responsible for capillary enlargement in Pdcd10 ECKO mice, we examined endothelial cell junctions and endothelial cell-periocyte interactions within the lesions. The lesions in Pdcd10 ECKO mice were characterized by a single layer of dilated endothelium with significantly reduced pericyte coverage, as seen in human CCM lesions ( Fig. 2a) . Endothelial cell-pericyte association, as visualized by gap junctional protein connexin 43 staining, was also drastically attenuated in CCM lesions relative to normal vessels ( Fig. 2a) . Endothelial adherens junctions, as visualized by VE-cadherin staining, were disorganized and were markedly fewer in number in lesion areas, as compared to normal vessels in the brains of WT mice ( Fig. 2b) . Similarly, tight junction coverage in lesions, as visualized by claudin 5 staining, was also drastically reduced ( Fig. 2b) . Quantitation analyses showed significant reductions of pericytes and the three types of cell junction within CCM lesions, as compared to normal microvessels ( Fig. 2c) . ANGPT2, secreted by endothelial cells, is classically considered to be an ANGPT1 antagonist, counteracting the stabilizing action of ANGPT1 and thereby increasing endothelial cell permeability 30, 31 . Although ANGPT2 was detected in the endothelial cells of normal vessels in the brains of WT mice, ANGPT2 levels were highly upregulated in the brain of Pdcd10 ECKO mice, both inside the dilated vessels and outside the lesions ( Fig. 2d) . ANGPT2 protein levels, as detected by ELISA, were highly increased in the cerebellum of Pdcd10 ECKO mice, as compared to WT mice. We also detected increased ANGPT2 levels in the retina, but not in lung tissue or blood ( Fig. 2e) , which is consistent with the location of the lesions. The expression of Angpt2 mRNA (but not of Angpt1 or Tek (also known as Tie2) mRNA) was increased weakly at P5 and strongly at P10 in the cerebellum of Pdcd10 ECKO mice ( Fig. 2f) . Unexpectedly, we detected increased levels of TIE2 phosphorylation in Pdcd10 ECKO brains, as assessed by western blotting (Fig. 2g) , which suggests the activation of ANGPT2-TIE2 signaling during CCM lesion development. Normal area Lesion area CD31 Claudin 5
Angpt2 Angpt1
Tek P5
Tek To determine whether ANGPT2 upregulation has clinical relevance, we examined the expression of ANGPT2 in human CCM3 lesions. We obtained paraffin blocks for eight cases of human CCM3 lesions. Six of the samples contained typical CCM lesions surrounded by relatively normal tissue, according to H&E staining, whereas the other two cases had severe vascular fibrosis ( Supplementary Fig. 3a ). ANGPT2 and pTIE2 staining was absent in normal brain areas, but was significantly upregulated in the CCM lesions of all eight cases, accompanied by the disruption of endothelial junctions ( Fig. 2h,i; Supplementary Fig. 3b-e ).
CCM3 restrains ANGPT2 secretion and maintains endothelial cell junctions
To determine whether CCM3 regulates ANGPT2 secretion via UNC13-dependent exocytosis in vascular endothelial cells, we first examined the expression of UNC13 family members in both mouse and human brain microvascular endothelial cells (MBMVECs and HBMVECs, respectively). UNC13B was the UNC13 isoform expressed predominantly, as detected by RT-qPCR ( Supplementary  Fig. 4a,b) . Moreover, we found that UNC13B forms a complex with CCM3 and the GCKIII family member STK24 (Fig. 3a) , and that CCM3 co-localized with the vesicle-associated membrane proteins VAMP3 and VAMP8 in HBMVECs (Fig. 3b) . To determine directly whether CCM3 regulates exocytosis in endothelial cells, we used VAMP8 fused to the pH-sensitive fluorescent protein PHluorin to visualize fusion processes of individual exocytic vesicles, as imaged using live-cell TIRF microscopy. HBMVECs were co-transfected with the PHluorin probe and a control short interfering (si)RNA or CCM3 siRNA in the presence or absence of an UNC13B siRNA. The knockdown efficiency and specificity of these siRNAs were verified by RT-qPCR ( Supplementary Fig. 4c ). Vesicle fusion events and kinetics were quantified for the individual fusion events recorded in the time-lapse TIRF images. CCM3 silencing in HBMVECs increased the number of exocytic fusion events without affecting the fusion kinetics; moreover, the increased number of fusion events was suppressed by the co-silencing of UNC13B ( Fig. 3c) . We next examined the direct effect of CCM3 deficiency on ANGPT2 expression and secretion in endothelial cells. WT and CCM3-depleted MBMVECs were isolated 32 and reconstituted by lentiviral transduction with CCM3-WT (1-212 aa) or CCM3-N (1-95 aa) (a loss-of-function CCM3 mutant encoded by a PDCD10 mutation found in individuals with CCM). ANGPT2 release was increased in CCM3-depleted MBMVECs when compared to WT cells, and this increase was attenuated by reconstitution with CCM3-WT, but not with CCM3-N ( Supplementary Fig. 4d ). In HBMVECs, the silencing of CCM3, but not of CCM1 or CCM2 protein, caused a significant increase in ANGPT2 secretion, and this augmented secretion could be significantly suppressed by co-silencing UNC13B (Fig. 3d,e ). The levels of Angpt2 mRNA, however (Supplementary Fig. 4c) , and total ANGPT2 protein ( Fig. 3f) were not significantly altered by the silencing of CCM3 or UNC13B. The increase in ANGPT2 secretion in CCM3-knockdown endothelial cells was associated with enhanced levels of phospho-TIE2. However, total TIE2 and ANGPT1 protein levels were not affected in these cells (Fig. 3f) . Consistently with previous findings that CCM3 stabilizes GCKIII kinases 33 , CCM3 knockdown in HBMVECs induced a reduction in STK24 levels, as compared to those in control cells (Fig. 3f) .
We next tested the effects of protein synthesis inhibition by cycloheximide (CHX) treatment on ANGPT2 release in HBMVECs. As we reported previously 34 , VEGFR2 (encoded by KDR) levels were dramatically reduced at 2 h after CHX treatment; by contrast, total ANGPT2, TIE2 and CCM3 protein levels were reduced only at 8 h after CHX treatment (Supplementary Fig. 4e ), which suggests that these proteins are relatively stable, consistent with previous work showing that CCM3 has a half life of ≥8 h 32 . CHX treatment had no effects on total or secreted ANGPT2 levels in control or CCM3depleted endothelial cells at 8 h after treatment (Fig. 3g) . These data are consistent with previous work indicating that ANGPT2 levels are regulated primarily at a step of protein release 28 . We detected npg localization of ANGPT2 in VAMP3-positive vesicles in CCM3-knockdown endothelial cells (Supplementary Fig. 4f ). Enhanced levels of ANGPT2 secretion and phospho-TIE2 in CCM3-depleted endothelial cells were blunted by the co-silencing of VAMP3 ( Supplementary  Fig. 4g,h) . We observed a similar role of CCM3 on vWF release and P-selectin surface expression in endothelial cells ( Supplementary  Fig. 4i,j) . These data demonstrate that CCM3 restrains exocytosis of ANGPT2 from the WPB in endothelial cells. Additionally, we examined whether CCM3-mediated ANGPT2 secretion contributes to endothelial-cell-junction and endothelial-barrier integrity. CCM3 knockdown dramatically disrupted both adherens and tight junctions, as detected by immunostaining for VE-cadherin and zonula occludens 1 (ZO1, encoded by TJP1), respectively. However, the co-silencing of UNC13B or treatment with anti-ANGPT2 antibody significantly normalized both adherens and tight junctions (Fig. 3h,i) . Co-silencing of UNC13B or anti-ANGPT2 antibody also restored barrier function in CCM3-ablated endothelial cells, as assessed by transendothelial electric resistance (TEER) using electrical cell-substrate impedance sensing 35 (Fig. 3j) .
CCM3-ANGPT2 axis regulates endothelial lumen formation and pericyte recruitment
To study how CCM3 regulates vessel lumen diameter, which was observed to be enlarged in the brain tissues of Pdcd10 ECKO mice, we analyzed endothelial cell sprouting and lumen formation using an optimized in vitro, endothelial-cell-sprouting and tube-formation model 36, 37 . When EGFP-expressing HBMVECs were seeded onto a confluent layer of fibroblasts, we observed that lumen formation peaked between days 7 and 14 after co-culture (data not shown). CCM3 knockdown resulted in enhanced endothelial cell sprouting and lumen formation, as visualized by VE-cadherin and collagen-IV staining ( Fig. 4a; Supplementary Fig. 5a,b) . Quantitative analyses indicated that the number of branch points, mean lumen diameter and lumenized (collagen-IV-covered) area 37,38 was significantly increased in the CCM3-knockdown group, as compared to that in the siCtrl group (Fig. 4a,b) . The enhancing effects induced by CCM3 knockdown on endothelial cell sprouting and lumen formation were not affected by control IgG treatment, but were blunted by either co-silencing of UNC13B or treatment with anti-ANGPT2 antibody (Fig. 4a,b) .
To further verify that CCM3 regulates lumen formation and pericyte recruitment, we performed a 3D spheroid sprouting assay in which endothelial cells were coated onto cytodex beads, followed by the embedding of the beads in fibrin gels. Fibroblasts cultured on top of the gel promoted optimal sprouting and tube formation, which peaked at day 8, as visualized by immunostaining with VE-cadherin ( Supplementary Fig. 5c-e ). Quantitative analyses indicated that the mean sprout length was not different between the control and CCM3-knockdown groups, but the number of sprouts was drastically increased by CCM3 knockdown. Moreover, we detected dilated lumen formation in the CCM3-knockdown group ( Supplementary  Fig. 5c-f) . Notably, the enhancing effects of CCM3 knockdown on endothelial cell sprouting and lumen formation in this assay were blunted by either co-silencing of UNC13B or treatment with anti-ANGPT2 antibody (Fig. 4c,d) .
The spheroid sprouting assay has been used as a system to study pericyte or smooth-muscle cell recruitment and vessel maturation 39 .
To visualize endothelial cells and pericytes in the sprouts, EGFPexpressing HBMVECs were transfected with a control or CCM3 siRNA and then seeded with mCherry-expressing normal human brain microvascular pericytes (HBMVPCs). Pericytes were recruited to control endothelial cells, but not to CCM3-knockdown endothelial 1 0 4 0 VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 nature medicine cells, during sprouting (Fig. 4e) . However, co-silencing of UNC13B in the endothelial cells or treatment with anti-ANGPT2 antibody, or a combination of both, restored pericyte recruitment to endothelial cell sprouts (Fig. 4e,f) . These data suggest that CCM3 maintains normal endothelial cell junctions, endothelial cell lumen formation and pericyte recruitment by restraining ANGPT2 exocytosis from endothelial cells.
Unc13b deficiency reduces ANGPT2 secretion and CCM lesions in Pdcd10 ECKO mice Unc13b −/− mice do not show gross phenotypes, but they develop seizures after 1 year of age, probably owing to a requirement for UNC13 function in the brain 40 . To test whether the suppression of elevated exocytosis rescues CCM-associated defects in CCM3-deficient mice, Pdcd10 ECKO ;Unc13b −/− (double knockout, DKO) mice were obtained by mating Unc13b −/− mice with Cdh5-CreERT2;Pdcd10 fl/fl mice, followed by feeding pups with tamoxifen at P1-P3. Brain tissue was harvested at P5 (early in lesion development) and P10 (full lesion development). No lesions were found in the brain of Unc13b −/− mice (Fig. 5a-c) . The numbers of lesions ( Fig. 5a-c) and enlarged vessels with defects in pericyte coverage in cerebellar sections (Fig. 5d,e ) were significantly reduced in DKO mice, as compared to those in Pdcd10 ECKO mice. Diffuse ANGPT2 staining surrounding dilated vessels and a concomitant increase in phospho-TIE2 staining of endothelial cells were detected in Pdcd10 ECKO mice, as compared to WT or Unc13b −/− mice, and these effects were normalized in DKO mice (Fig. 5f,g) . Total ANGPT2 protein levels in brain tissue were weakly upregulated by CCM3 deficiency, and this effect was normalized by Unc13b deletion, as measured by ELISA and western blotting (Fig. 5h,i) . Similarly, ANGPT2 secretion was increased significantly in brain endothelial cells isolated from the diseased brain of Pdcd10 ECKO mice, and this effect was also normalized by co-deletion of Unc13b (Fig. 5j) . These results strongly suggest that UNC13B deficiency, by suppressing ANGPT2-TIE2 signaling in endothelial cells, attenuates the neurovascular phenotype caused by Pdcd10 inactivation.
ANGPT2-neutralizing antibody blocks CCM lesion formation in
Pdcd10 ECKO mice Anti-ANGPT2 antibody strongly inhibits angiogenesis at high doses 38, 41 . When administered by intraperitoneal (i.p.) injection at 10 µg/g (body weight) from P2 and every other day thereafter, we observed modest inhibitory effects of anti-ANGPT2 on retinal angiogenesis (~22%) and brain vascular density (~10%) ( Supplementary  Fig. 6 ). By contrast, ANGPT2 neutralization dramatically reduced the number of CCM lesions in Pdcd10 ECKO mice, as compared to untreated mice, as visualized by whole-mount and H&E staining ( Fig. 6a-c) . We further tested the combinatory effects of ANGPT2 antibody treatment and Unc13b deficiency on CCM lesion development. ANGPT2-antibody administration to DKO mice completely abrogated CCM lesion formation in the brain (Fig. 6a-c) and in the retina (Supplementary Fig. 7a-c) . Chondroitin sulfate proteoglycan 4 (CSPG4, also known as NG2)-positive pericyte coverage of CD31 + microvessels was enhanced by ANGPT2-antibody treatment, from 20% in IgG-treated Pdcd10 ECKO mice to more than 80% in ANGPT2-antibody-treated Pdcd10 ECKO mice, and pericyte coverage was almost 100% in ANGPT2-antibody-treated DKO mice (Fig. 6d,e ). We observed similar results for endothelial cell adherens and tight junctions (Fig. 6d,e ). Next, we determined whether the therapeutic effects of ANGPT2 antibody were associated with effects on ANGPT2-TIE2 signaling in vivo. Diffuse ANGPT2 staining surrounding dilated vessels, increased phospho-TIE2 staining in endothelial cells and an increase in total ANGPT2 protein were all observed in Pdcd10 ECKO mice, as compared to WT mice; these defects were normalized by ANGPT2-antibody treatment of Pdcd10 ECKO and abolished by ANGPT2-antibody treatment of DKO mice ( Fig. 6f-i) .
Taken together, these data support the conclusion that CCM3 deficiency induces ANGPT2 secretion from endothelial cells, which disrupts endothelial cell junctions and endothelial cell-pericyte association and contributes to the CCM disease phenotype.
DISCUSSION
In this study, we report that CCM lesions in mice with an endothelialcell-specific Pdcd10 gene deletion (Pdcdc10 ECKO ) exhibit cerebellar hemorrhage with disrupted endothelial cell junctions and endothelial cell-pericyte associations, which is correlated with increased ANGPT2 secretion surrounding dilated cerebral microvessels. This enhanced ANGPT2 secretion was observed in brain and retinal tissue, but not in lung tissue or blood. This type of brain-and retinaspecific effect of CCM3 on ANGPT2 secretion provides a possible explanation for the restriction of CCM lesions to the brain and retina of endothelial-cell-specific, CCM3-deficient mice. Studies in vitro confirmed that CCM3 deficiency in endothelial cells causes a disruption of endothelial-cell junctions, enlarged lumen formation and reduced pericyte recruitment during sprouting and tube formation, as compared to WT cells. These endothelial-cell phenotypes are associated with augmented ANGPT2 release and secretion, and they are substantially attenuated by the inhibition of exocytosis or neutralization of ANGPT2, which suggests that CCM3 maintains normal endothelial cell junctions, lumen formation and vessel maturation by restraining exocytosis-mediated ANGPT2 release from endothelial cells. Mechanistic studies using confocal and TIRF microscopy analyses suggested that CCM3, by suppressing UNC13B-and VAMPdependent exocytosis, regulates ANGPT2 release from WPBs in brain endothelial cells. Using mouse genetic approaches, we showed that Unc13b-deficiency prevents the disruption of endothelial-cell junctions and vessel dilation and blocks CCM lesion development in the brain of endothelial-cell-specific, CCM3-deficient mice. Notably, an ANGPT2-neutralizing antibody ameliorates CCM lesion progression in the mouse CCM model, which is associated with normalization of endothelial cell junctions, endothelial cell-pericyte interaction and vascular integrity. Our study reveals a new mechanism by which PDCD10 mutation contributes to the progression of the CCM disease ( Supplementary Fig. 8) , and thus offers a potential therapeutic approach to this presently incurable pathology. We recently demonstrated that CCM3, in a complex with GCKIII kinases, binds to the C2B domain of UNC13 and inhibits its binding to plasma membrane lipids-a step required for exocytosis 24 . In the present study, we provide strong evidence that CCM3, through its effects on UNC13B-and VAMP-dependent exocytosis, controls ANGPT2 secretion in endothelial cells. We found that UNC13B is the primary isoform expressed in vascular endothelial cells, and that UNC13B forms a complex with CCM3 and the GCKIII member STK24 in endothelial cells. By confocal microscopy, we showed that CCM3 co-localizes with VAMP3 and VAMP8 in brain endothelial cells, and by real-time TIRF microscopic analyses, that CCM3 depletion increases exocytic fusion events, which can be suppressed by co-silencing UNC13B. Depletion of CCM3 (but not of CCM1 or CCM2) in brain endothelial cells strongly augments ANGPT2 secretion from the cells, which could be blocked by co-silencing of UNC13B or VAMP3. However, Angpt2 mRNA and total ANGPT2 protein are not dramatically altered by CCM3 npg a r t i c l e s nature medicine VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 1 0 4 1 deletion in endothelial cells, and ANGPT2 protein stability and secretion are not altered in CCM3-depleted endothelial cells, which supports the concept that the primary mechanism for the increase in ANGPT2 release resulting from CCM3 deficiency is exocytosis rather than effects on protein synthesis or stability. Using genetic approaches involving Pdcd10-and Unc13b-deficient mice, we observed similar regulatory patterns of ANGPT2 secretion by CCM3 and UNC13B in mouse brain and retinal tissue. Although Angpt2-deficient mice are viable 42 , ANGPT2 is required for postnatal angiogenesis and lymphatic patterning 42 . Defects in ANGPT2 function might cause glaucoma, a disease that leads to blindness 43 . For clinical translation of the finding that treatment with a ANGPT2-neutralizing antibody attenuates CCM lesions in CCM3-deficient mice, it might be necessary to optimize the dose of the antibody to achieve a maximal anti-CCM effect, with minimal side effects on physiological vascular development and function.
The TIE2-signaling pathway has distinct roles in both vascular quiescence and angiogenesis. These effects have been attributed to distinct TIE2-signaling complexes assembled by ANGPT1, such that phospho-TIE2 is located at endothelial cell-endothelial cell contacts in the quiescent state, but at endothelial cell-matrix contacts during angiogenesis 44, 45 . Although ANGPT2 acts as a negative regulator of ANGPT1-TIE2 signaling in quiescent endothelial cells, it is capable of inducing TIE2 phosphorylation in stressed endothelial cells 38, 46 . We observed increased ANGPT2-TIE2 signaling in CCM3-depleted endothelial cells, consistent with a report that PDCD10 deletion induces several forms of stress-related signaling in endothelial cells 47 . Our data indicate that increased ANGPT2 secretion in both CCM3-depleted brain tissues and brain endothelial cells correlates with enhanced phospho-TIE2 levels. It is plausible that ANGPT2 antagonizes ANGPT1 in quiescent endothelial cells to inhibit TIE2 activation, whereas it synergizes with ANGPT1 in inducing TIE2 phosphorylation to promote angiogenesis, and our data clearly demonstrate that enhanced ANGPT2-TIE2 signaling contributes to CCM pathogenesis. The pathological consequences of increased ANGPT2-TIE2 signaling resulting from CCM3 loss might, however, be different from the consequences of the acute ANGPT2-TIE2 activation that occurs during acute inflammation such as sepsis 48 ; CCM3 loss, but not sepsis, has strong effects on increasing endothelial lumen dilatation. Loss of CCM1 or CCM2 in endothelial cells activates several signaling pathways, including RhoA 49 , MEKK3-ERK5-Krüppel-like factor (KLF) 2/4 signaling 20, 50 and KLF4-TGF-β-Smad-mediated endothelial-mesenchymal transition (EndMT) 16, 50 . It needs to be further defined whether the CCM3-UNC13-ANGPT2-TIE2 axis participates in cross-talk with these pathways. Notably, ANGPT1-TIE2, acting via PI3K-Akt activation, induces the expression of KLF2 in quiescent endothelial cells 51 . It is possible that in CCM3-depleted endothelial cells, ANGPT2, acting via TIE2, induces KLF2 protein expression, which serves as a point of convergence for CCM3-mediated, ANGPT2-TIE2 signaling and CCM1/2-mediated MEKK3-ERK5 signaling.
The modulation of endothelial cell junctions is emerging as a common mechanism by which defects in signaling pathways resulting from mutations (in humans) or deletions (in postnatal mice) in any of the three CCM genes result in similar CCM lesions. CCM1, in a complex with CCM2, binds to and regulates several proteins that are directly involved in endothelial cell junctions and junction-associated complexes, such as RAP1, heart-development protein with EGFlike domains 1 (HEG1) and integrin cytoplasmic domain-associated protein 1 (ICAP1, encoded by ITGB1BP1) [52] [53] [54] . Our data from studies both in vitro and in vivo demonstrate that CCM3, by restraining ANGPT2 secretion, regulates both adherens and tight junctions in brain endothelial cells. It remains unknown exactly how alterations of endothelial cell junctions are linked to CCM lesion development. A common phenotype of CCM gene deletions is enlarged lumen formation, and it is known that endothelial-cell-junction organization directly regulates endothelial lumen formation 55 . In the early mouse embryo, a homozygous null mutation of the gene encoding VE-cadherin (Cdh5) results in enlarged lumens of cephalic vessels, although the lumenal sizes of the aorta and cardinal veins are reduced, as compared to those in WT mice 56, 57 . Mechanistic studies suggest that CCM1-VE-cadherin affects the association of the adherens junction with the polarity complex to regulate vascular lumenal structure 55 , and that CCM3 might have similar effects. Alternatively, CCM3-mediated exocytosis might directly contribute to lumen formation. It is now accepted that lumen formation involves the structured expansion of the apical plasma membrane through the general mechanism of vesicle transport 58 . This idea is supported by recent reports from genetic studies of tracheal tubule formation in Drosophila. Mutant flies with loss-of-function mutations in the genes encoding orthologs of CCM3 or GCKIII kinase have dilated tracheal tubes, which resemble the dilated blood vessels found in people with CCM 59 . This tube-dilation phenotype can be suppressed by a reduction in the expression of NSF2, a protein involved in SNARE recycling and the secondary phase of exocytosis. Moreover, CCM lesions are found predominantly in vessels of the brain and retina, which are notable for having an extraordinarily high pericyte-to-endothelial-cell ratio, thereby forming a highresistance blood-brain barrier or blood-retinal barrier, which is further supplemented by astrocyte foot processes. Our in vitro model study indicated that a loss of CCM3 in endothelial cells causes dilated lumen with impaired pericyte recruitment, recapitulating the CCM lesion phenotype in vivo, and thus indicates that ANGPT2 has a crucial role in the modulation of CCM3-mediated endothelial cellpericyte interactions. The identification of ANGPT2 as a CCM3 (but not CCM1 or CCM2)-downstream effector might explain why PDCD10 mutations in humans often result in a more severe form of the disease, as compared to mutations in KRIT1 or CCM2.
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